Objectives: Quinolone resistance in the opportunistic pathogen Pseudomonas aeruginosa is commonly caused by mutations that alter the target molecules DNA gyrase/topoisomerase IV, or cause activation of various efflux systems. We have analysed the effect of quinolone resistance caused by DNA gyrase/topoisomerase IV mutations on bacterial fitness.
Introduction
Pseudomonas aeruginosa is an important cause of opportunistic nosocomial infections including wound, urinary and respiratory tract infections. The most important risk group is patients with cystic fibrosis, in whom P. aeruginosa infection is the leading cause of mortality. 1 Antibiotic resistance is a significant problem in the treatment of P. aeruginosa infections, partly because the bacterium is intrinsically resistant to a wide range of antibiotics due to low outer membrane permeability and the presence of several drug efflux systems. 2 The major classes of antibiotics used for treatment include penicillins, cephalosporins, carbapenems, aminoglycosides, polymyxins and quinolones. 1 Cystic fibrosis patients with P. aeruginosa infections are commonly treated with quinolones, since they are at present the only antibiotics available for effective oral administration. 3, 4 However, quinolone resistance can rapidly develop during treatment. A recent survey from the UK showed that 30% of P. aeruginosa isolates from cystic fibrosis patients are resistant to quinolones, which is similar to reported frequencies in the USA. 5 Quinolones act by inhibiting the target enzymes DNA gyrase and topoisomerase IV, each comprised of two subunits: GyrA and GyrB, and ParC and ParE, respectively. 6 Quinolones block replication and cell growth by trapping DNA gyrase on DNA as a DNA-gyrase -antibiotic complex, in which both DNA strands are broken. 6 Resistance to quinolones is mediated by mutations in DNA gyrase, topoisomerase IV as well as by mutations in regulatory genes for different efflux systems. 1, 7 Furthermore, plasmid-borne resistance to quinolones has been reported in Klebsiella pneumoniae and Escherichia coli and in these cases the plasmids carry a quinolone-resistance gene (qnr) encoding a protein that blocks the inhibition of DNA gyrase caused by the drug. [8] [9] [10] DNA gyrase is the primary target of quinolones in Gram-negative bacteria, and a majority of the resistance mutations found in gyrA and gyrB are clustered to the respective quinolone resistance-determining regions (QRDRs). 11 Antibiotics target functions essential for bacterial survival, such as DNA gyrase, RNA polymerase, the ribosome and cell wall biosynthetic enzymes. Mutations in these targets that lead to resistance are commonly associated with a fitness cost, observed as a reduced growth rate and/or virulence in the absence of antibiotic. 12, 13 Bacteria can, in many cases, compensate for their loss of fitness by accumulating compensatory mutations that partly or fully restore the function impaired by the resistance mutation. 12, 13 The biological cost of antibiotic resistance in P. aeruginosa has been examined in mutants that overproduce multidrug resistance efflux pumps.
14 These mutants showed a reduced fitness, which was observed as decreased survival in water, impaired production of phenazines and proteases, as well as lowered virulence. Since quinolones are commonly used for treatment of Pseudomonas infections, and the major mechanism of resistance is by alteration of topoisomerases, we wanted to study the fitness of such resistant mutants.
Materials and methods

Isolation of resistant mutants
From several independent 1 mL Luria-Bertani (LB) cultures, norfloxacin-resistant mutants were isolated by plating 10 8 -10 9 P. aeruginosa PAO1 cells on Luria agar (LA) plates containing 2, 8 or 80 mg/L norfloxacin (Sigma). The plates were incubated at 378C and one colony from each independent culture was collected. Resistant mutants were purified by two successive single-colony isolations on plates containing the same concentration of norfloxacin and subsequently frozen at À708C. One mutant isolated on 8 mg/L norfloxacin was chosen for further selection on 80 mg/L norfloxacin (see below). Bacterial cells were grown in LB broth at 378C. MICs were determined by using the Etest (AB Biodisk, Solna, Sweden).
Clinical isolates
Twenty quinolone-resistant P. aeruginosa isolates from Danish cystic fibrosis patients have been characterized and described previously and were kindly provided by Nils Høiby. 4 
Isolation of compensatory mutations
Two slow-growing norfloxacin-resistant gyrA mutants, DA6254 (mutation ACC83ATC) and DA6252 (mutation GAC87TAC), were chosen for selection of compensated mutants. Evolution experiments were performed by serial transfer of 10 6 bacteria to 1 mL of fresh LB medium and growth at 378C to a final density of 10 9 cells/mL before the next transfer. Samples were taken daily from each culture and streaked on LA plates, and the colony size was compared with the susceptible parent and the resistant mutant. The cultures were cycled until the majority of the cells showed a faster growth phenotype (larger colonies). As a control experiment, several lineages of the susceptible parental strain PAO1 were cycled in parallel and during that time no changes were seen in the growth rate of these lineages.
Mutation rates
Independent cultures were inoculated with 10 3 cells and grown overnight. Undiluted cultures were plated on LA, norfloxacin plates at the indicated concentrations (2 and 8 mg/L) to determine the number of resistant mutants. Suitable dilutions were plated on LA plates to determine the number of cells present in the cultures. Mutation rates (m) to fluoroquinolone resistance were calculated according to the equation: m = lnP 0 /N where P 0 designates the ratio of the number of cultures without mutants divided by the total number of cultures, and N designates the total number of bacteria plated. 15 The compensatory mutation rate was calculated according to a previously described theory. 16, 17 Growth rate and biofilm measurements
The growth rates of the isolated mutants were determined using a Bioscreen C Analyzer System (Labsystems, Helsinki, Finland). $ 10 6 cells were inoculated into 400 mL of LB on a bioscreen plate and incubated with continuous shaking at 378C. The absorbance was measured at 540 nm. Each strain was assayed in four independent cultures in two separate experiments. Relative growth rates were calculated as the ratio of the growth rate of the reference strain divided by the growth rate of the test strain. Growth rates of clinical isolates were related to the most-fit strain, which had a growth rate similar to P. aeruginosa PAO1. Measurement of biofilm formation was performed according to the method described by O'Toole et al 18 .
PCR amplification
Chromosomal DNA from the isolated P. aeruginosa mutants was prepared using a DNeasy kit (Qiagen Inc.) and subjected to PCR. PCR amplification of the QRDR of the gyrAB and parCE genes, as well as the complete coding sequence of the mexR and nfxB genes, was carried out with primers designed by Jalal & Wretlind. 19, 20 The oligonucleotide primers used for PCR amplification and DNA sequencing for the complete genes of gyrAB, parCE and the other sequenced genes (topA, hupN, fis, hupB, himAD and PA5348) are described in Table 1 . The PCR reaction was run under the following conditions: denaturation for 5 min at 948C, followed by 30 cycles of 948C for 30 s, 588C for 30 s and 728C for 1 min, and a final extension step of 7 min at 728C. The reactions were performed with AmpliTaq DNA polymerase (Applied Biosystems) in a DNA thermal cycler, GeneAmp PCR System 2400 (Perkin-Elmer). The PCR products were analysed by agarose gel electrophoresis, stained with ethidium bromide and visualized under UV light.
DNA sequencing
PCR products were purified using GFX PCR DNA and a Gel Band Purification Kit (Amersham Pharmacia Biotech Inc.). Purified PCR products were processed for DNA sequencing using a BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Warrington, UK) in the ABI 3100 Genetic Analyzer (Perkin-Elmer).
Gel electrophoretic separation of topoisomers
Plasmid RSF1010 was transferred by electroporation to the parental susceptible strain PAO1, two resistant gyrA mutants, DA6254 (ACC83ATC) and DA6252 (GAC87TAC), and compensated mutants from these strains. Plasmid DNA was isolated using a Qiagen plasmid purification kit (Qiagen Inc.) and analysed by agarose gel electrophoresis in the presence of chloroquine, as previously described by Matsuo et al. 21 with some modifications. Agarose gels (1%) were run for 22 h at 2 V/cm in 1 Â TAE buffer containing 5 mg/L chloroquine and were washed for 3 h in distilled water before staining with ethidium bromide. At this concentration of chloroquine, topoisomers that were more supercoiled prior to electrophoresis migrated more rapidly through the gel. Fitness burden of quinolone resistance RNA purification and synthesis of cDNA Bacteria, grown in LB broth in the logarithmic phase, were harvested by centrifugation at 3000g for 10 min. The supernatants were discarded and the pellets re-suspended in 500 mL of 10 mM Tris, pH 8.0. Cell density was adjusted to $ 1.5 Â 10 8 cells/mL, as determined by comparison with a McFarland standard no. 0.5. The cell suspensions were kept on ice during these procedures. The suspensions (200 mL; $ 0.3 Â 10 8 cells) were used for isolation of total RNA by the protocol described in the High Pure RNA Isolation Kit (Roche Diagnostics, Mannheim, Germany). The total elution volume of RNA was 50 mL at the final step. RNA was stored at À708C until used in a cDNA preparation reaction. The concentration of RNA was determined spectrophotometrically at 260 nm. Total RNA (1 mg) was used as a template for reverse transcription (RT) in 20 mL volumes, as described in the 1st Strand cDNA Synthesis Kit for RT-PCR (Roche). In the RT reaction, we used random primers p(dN) 6 . The cDNA was stored at À208C until used in real-time PCR in a LightCycler (LC; Roche).
Real-time PCR
The primers are described in Table 2 . A master mix containing 4 mM MgCl 2 and 2 mM each gene-specific primers was prepared on ice using a LightCycler-FastStart DNA Master SYBR Green I kit (Roche). Eighteen microlitres of master mix was combined with 2 mL cDNA in the capillaries, which were sealed and placed in the LightCycler. The following temperature profile was used for realtime PCR: after initial denaturation at 958C for 600 s, amplification was carried out for 45 cycles with denaturation at 958C for 15 s, annealing at 628C for 5 s and extension at 728C for 16 s. The temperature transition rate was 208C/s. Melting curve analysis was conducted in one cycle with three segments: 958C for 60 s, 678C for 60 s and 958C for 0 s. The temperature transition rate was 208C/s for the first and second segments and 0.18C for the third segment. mRNA for the ribosomal protein RpsL was used as a reference in the real-time PCR assay and the relative amount of mRNA for efflux pump proteins (not shown) was calculated, based on the standard curve and for DNA gyrase as well as topoisomerase IV, where 3.4 cycles caused a 10-fold increase in the PCR product. A strain was considered to hyperproduce mexB mRNA if the cDNA level was >3 Â wild-type (MexB is produced constitutively). For the other proteins, the limit was >10 Â wild-type. 20 In control experiments without reverse transcriptase or RNase-treated samples, no PCR product was obtained.
Results
Selection and characterization of norfloxacin-resistant mutants
We isolated norfloxacin-resistant mutants on three different concentrations of norfloxacin (2, 8 and 80 mg/L) to obtain a broad spectrum of mutants. Ten mutants from each selection condition were chosen for further investigation. We examined their resistance mechanism and determined the effect of these mutations on bacterial growth and biofilm formation. One mutant with each type of mutation is presented in Table 3 . The mutation rate to norfloxacin resistance for mutants isolated on 2 and 8 mg/L was determined to be 1 Â 10 À9 . Since these were spontaneous mutants they are likely to be single-point mutations. We identified the resistance mechanism by sequencing the gyrAB genes. The majority of the mutants (17/20) isolated on these concentrations of norfloxacin had a mutation in the QRDR of either gyrA or gyrB. Six of 20 mutants had a mutation in gyrA at codon 83 (ACC ! ATC), which is the most reported target for quinolone resistance in several species. 7 Resistance mutations were also identified at codon 87 in gyrA as well as at codon 323, 467 and 469 in gyrB. In addition, another rarely reported mutation was identified in gyrA at codon 83, ACC ! GCC. Three mutants had no mutation in the QRDR of gyrA, gyrB, parC or parE or in the nfxB or mexR genes. Twelve of the 20 mutants isolated on 2 and 8 mg/L norfloxacin showed increased resistance to tetracycline (MIC equal or greater than 48 mg/L) in addition to norfloxacin resistance. Resistance to tetracycline and quinolones may be mediated by increased expression of efflux systems, such as MexAB-OprM and MexCD-OprJ, which are regulated by mexR and nfxB, respectively 1 . We did not identify any mutations in these genes. However, we also analysed the mexB and mexD mRNA transcript levels using real-time PCR. Six of the 12 mutants with increased resistance to tetracycline showed a 5-to 1000-fold increased expression of MexD (data not shown). The remaining six tetracycline-resistant mutants could have alterations in other efflux systems. 22 A high level of quinolone resistance is generally caused by multiple mutations. 7,23 -25 We used a gyrA (ACC83ATC) mutant for isolation of resistant mutants on 80 mg/L of norfloxacin. All mutants isolated on a high concentration of norfloxacin showed a high level of resistance to norfloxacin (>256 mg/L) and additional mutations were identified in parC, parE and nfxB (Table 3 ). In nfxB, one insertion, two substitutions and three deletion mutations were identified. This is in contrast to clinical isolates where only base substitutions in nfxB have been reported. 4, 19, 25 The six strains with mutations in nfxB showed, as expected, increased tetracycline resistance and expression of the mexD transcript (data not shown).
Fitness effects of norfloxacin resistance
The fitness of quinolone-resistant mutants was measured as growth rate in LB medium and the ability of the strains to form biofilm in microtitre dishes. Among the resistant strains with a single mutation in gyrA or gyrB, only three out of eight mutation types showed fitness costs when measured as growth rate in vitro (Figure 1) . One of the six mutants with a gyrA mutation at codon 83 (ACC ! ATC), DA6254, showed a reduced fitness. In addition, another mutant with a single mutation in gyrA, DA6252, also showed reduced growth rate. Both DA6254 and DA6252 were subjected to compensatory evolution (see below). The third type of mutation that showed decreased fitness was the gyrB (GAG469GAC) mutant, DA6249. However, this mutant also showed increased tetracycline resistance and expression of mexD, indicating that it had an additional unidentified mutation. In strains with double mutations and high-level resistance, considerable reductions in growth rate were seen for all strains. In addition, we examined the fitness of several non-isogenic clinical isolates obtained from cystic fibrosis patients. These clinical isolates have been characterized previously and the majority of these strains have resistance mutations in several targets. 4 In spite of the non-isogenicity of these strains, which might be expected to confound any correlation between resistance level and fitness, a weak negative correlation between fitness and level 
a Strains DA6218, DA6219, DA6222 and DA6234 were isolated on 2 mg/L norfloxacin. DA6243, DA6249, DA6252, DA6254 were isolated on 8 mg/L norfloxacin. DA7227, DA7229, DA7230, DA7232, DA7233, DA7234 and DA7235 were isolated on 80 mg/L norfloxacin. b NOR, norfloxacin; TET, tetracycline. Indicates that the gene was sequenced but that no mutations were found. ND, not determined. d Some of these mutants showed a significantly increased tetracycline resistance (>48 mg/L) suggesting that apart from the gyrA/gyrB mutation they contain an additional unidentified mutation. Fitness burden of quinolone resistance of resistance was still seen (Figure 2) . Thus, the growth rate of strains with MIC values of 8 and 16 mg/L norfloxacin appeared lower than for strains that were inhibited at 2 mg/L (P<0.05, determined using one-sample t-test confirmed by Mann -Whitney U-test). We also measured biofilm formation in the resistant mutants, but no correlation between growth rates in LB medium or MIC values and the ability to form biofilm could be seen. Thus, the susceptible parent strain and the resistant mutants isolated in vitro showed similar levels of biofilm formation. The clinical isolates, on the other hand, formed little biofilm, as compared with strain PAO1 and its mutant derivatives (data not shown). We do not know the reason for the reduced biofilm formation, but it is unlikely to result from the reduced growth rate per se since the slow-growing mutant derivatives of PAO1 still showed normal biofilm formation.
Compensatory evolution
Two low-fitness resistant clones, DA6252 and DA6254, with single mutations in gyrA (GAC87TAC and ACC83ATC, respectively) were subjected to compensatory evolution by serial passage in LB medium. The ACC83ATC mutant chosen for compensatory evolution is likely to carry an additional unknown mutation since its growth rate was reduced as compared with other independently isolated ACC83ATC mutants. After only 20-30 generations of growth, compensated mutants had appeared that showed a growth rate similar to the susceptible parent ( Figure 1) . In a control experiment, we serially passaged the susceptible parent strain. No changes in fitness were seen in this strain, indicating that the compensatory mutations found are specific suppressors of the resistance mutations and that they are not causing a general gain in fitness. Although the compensated strains retained the original resistance mutation, the MIC of norfloxacin decreased significantly from 64 mg/L (DA6252) and 48 mg/L (DA6254) to 12 mg/L. The fitness of the compensated strains was also investigated by measuring growth at 308C and 428C. All compensated mutants grew as well as wild-type at both 308C and 428C. However, biofilm formation at 378C was slightly decreased (data not shown). From the kinetics of appearance of fast-growing mutants, the population sizes during serial passage and the fitness of the resistant and compensated mutants, we could calculate the mutation rate for compensatory mutations to $ 10 À6 /cell/generation.
16,17
DNA supercoiling
We investigated alterations in supercoiling by electroporating the 8.7 kbp plasmid RSF1010 into the susceptible, resistant and compensated strains. Plasmid DNA was isolated and analysed by agarose gel electrophoresis in the presence of chloroquine. The topology of reporter plasmid DNA is thought to reflect the chromosomal topology. Chloroquine is an intercalating ligand that introduces supercoiling of closed circular DNA in the positive direction and without changing the linking number. 26 The relative positions of the topoisomer with the average linking number gives an estimate of the mean degree of supercoiling of the DNA. At the chloroquine concentration used in this assay, 5 mg/L, negatively supercoiled forms show greater mobility than relaxed topoisomers. The majority of DNA from the susceptible parent strain was negatively supercoiled, illustrated by the highest mobility (Figure 3, lane 1, bottom band) . Resistant strains were shifted to lower mobilities ( Figure 3, lanes 2 and 5) , indicating decreased supercoiling, whereas growth-compensated strains showed topoisomer distribution patterns similar to the susceptible parent ( Figure 3, lanes 3, 4 and 6 ). These results show that the decreased fitness associated with these two gyrA resistance mutations is caused by decreased supercoiling and that the compensatory mutations act to restore supercoiling to normal levels.
Mechanism of compensation
Since the fitness alterations in the resistant mutants and the compensated mutants were associated with changed supercoiling it is likely that the compensated mutants have acquired mutations that increase supercoiling to counteract the action of the gyrA mutation. The degree of supercoiling in DNA is determined by the balance between DNA-relaxing activity and DNA-supercoiling activity, regulated by the opposing actions of topoisomerase I and DNA gyrase, respectively. 27 To try to identify the compensatory mutations, we sequenced the complete topA, gyrAB and parCE genes and their corresponding promoter regions from the resistant and compensated mutants, but no additional mutations were identified. Another possibility could be increased expression of the DNA gyrase or topoisomerase IV genes, but we could not detect any differences in the expression of these genes (data not shown). Other proteins thought to affect supercoiling are the histone-like proteins HU (encoded by hupB), integration host factor (encoded by himAD) and the DNA binding protein Fis (encoded by fis). In addition, P. aeruginosa has two probable DNA binding proteins similar to HU, annotated PA3940 (hupN) and PA5348. However, no mutations were detected in any of these genes or promoter regions.
Discussion
DNA gyrase is the primary target of quinolones in Gramnegative bacteria. In this study, we isolated norfloxacin-resistant mutants from P. aeruginosa and identified the resistance mutations. Most (5/8) of the mutants isolated on low and intermediate concentrations of norfloxacin showed a low level of resistance and no reduction in fitness, as measured by growth rate in rich medium (with the exceptions of the gyrA GAC87-TAC, the gyrB GAG469GAC and one of the gyrA ACC83ATC mutants). Six out of 20 mutants had a gyrA ACC83ATC mutation, which is the most commonly found mutation in clinical isolates. 4, 19, 24, 25, 28, 29 Only one of these strains, DA6254, showed decreased fitness, whereas the others showed no cost. However, DA6254 could rapidly compensate for this cost and restore fitness to wild-type levels. The high prevalence of this mutant in patients could be explained by the low cost seen in the majority of these mutants and the rapid compensation when there is a fitness cost associated with this type of mutation. All high-level resistant mutants isolated in a second step from a gyrA mutant showed significantly reduced fitness.
The decreased fitness is associated with changed supercoiling. Thus, it was seen that two resistant mutants with reduced growth rate had decreased supercoiling (Figure 3) . One of these mutants, DA6252, has a resistance mutation at codon 87 in gyrA, and this target has previously been shown to reduce supercoiling activity in E. coli. 30, 31 However, the second strain that showed decreased supercoiling, DA6254, has a mutation in gyrA at codon 83 and this target has not been associated with any changes in supercoiling activity in E. coli. 30, 31 Decreased supercoiling indicates the presence of a less efficient DNA gyrase, which could cause increased accumulation of positive supercoils in front of a replication fork or transcription complex. 6 This could, in turn, slow replication/transcription and thereby reduce the growth rate. Resistant mutants with a reduced fitness could rapidly accumulate additional compensatory mutations that restored growth to the wild-type level. These mutations most likely act to restore supercoiling to the normal level ( Figure 3 ). However, we have sequenced most of the target genes known or predicted to affect the level of supercoiling without identifying any compensatory mutations. In addition, we investigated the expression of the DNA gyrase or topoisomerase IV genes, but could not detect any changes in the levels of these transcripts. It is notable that the compensatory mutations arose at a high rate (about 10 À6 ), which is much higher than that expected for a typical spontaneous point mutation (10 À11 to 10
À9
). 32 One possibility is that compensation can occur by any type of loss-of-function (deletion, insertion, base pair substitution etc.) mutation in an unknown gene, which would be expected to result in a high mutation rate. 32 The cost of quinolone resistance caused by topoisomerase mutations has been studied in E. coli, 30 Salmonella typhimurium, 33 Streptococcus pneumoniae 34 and Staphylococcus aureus.
35
The primary target of quinolones differs between Gram-negative and Gram-positive bacteria, being DNA gyrase and topoisomerase IV, respectively. The biological cost of quinolone resistance differs between different bacteria and depends on the level of resistance and the number of resistance mutations. For the five bacterial species examined, highly resistant mutants with multiple mutations show a significantly reduced fitness. However, for low-level resistant mutants with single mutations the cost Figure 3 . Gel electrophoresis assay of plasmid DNA isolated from the susceptible parent strain PAO1 (lane 1), and norfloxacin-resistant and growthcompensated strains. Plasmid DNA was run on 1.0% agarose gel containing 5 mg/L chloroquine. The direction of migration was from top to bottom. Under these conditions, the more negatively supercoiled plasmids migrate more rapidly. Lane 1, susceptible parent PAO1; lane 2, resistant strain DA6252 with a gyrA (GAC87TAC) mutation; lanes 3 and 4, growth-compensated strains of DA6252 with a gyrA (GAC87TAC) mutation and unknown compensatory mutations; lane 5, resistant strain DA6254 with a gyrA (ACC83ATC) mutation; lane 6, growth-compensated DA6254 with a gyrA (ACC83ATC) mutation and unknown compensatory mutation.
Fitness burden of quinolone resistance depends on the bacterial species. Thus, no or low cost was seen in S. pneumoniae 34 and S. typhimurium, 33 whereas single, lowlevel resistance mutations conferred a variable cost in E. coli depending on strain background. 30 Similar to our findings, compensatory mutations that reduce costs have been observed in some other species (S. typhimurium and S. aureus). 33, 35 For S. typhimurium the specific mechanism of compensation is not understood, but for S. aureus compensation appears to involve increased expression of the gyrAB and topB transcripts. 35 In conclusion, the present study shows that 'no cost' and compensatory mutations are common in quinolone-resistant P. aeruginosa. The clinical occurrence of these types of mutations is likely to contribute to the long-term persistence of resistant bacteria, underlining the importance of implementing efficient strategies to treat and prevent spread of resistant strains before they have become stably established in bacterial populations. 13 
